Wasatch Advisors LP Maintains 7.0% Stake in Sangamo Therapeutics
Ticker: SGMO · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | SC 13G/A |
| Filed Date | Feb 9, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech
TL;DR
**Wasatch Advisors LP still owns 7.0% of Sangamo Therapeutics, holding 12.4M shares.**
AI Summary
Wasatch Advisors LP, an investment adviser, has updated its ownership stake in Sangamo Therapeutics, Inc. (SGMO) to 7.0% of the common stock, holding 12,397,924 shares with sole voting and dispositive power as of February 9, 2024. This represents a notable position for Wasatch, indicating their continued conviction or strategic adjustment in the gene therapy company. For investors, this filing shows a significant institutional holder maintaining a substantial stake, which can be interpreted as a vote of confidence in Sangamo's long-term prospects, or at least a continued interest in their investment.
Why It Matters
This filing confirms a major institutional investor's continued significant ownership in Sangamo, which can influence market perception and potentially provide stability to the stock.
Risk Assessment
Risk Level: low — This filing is an update to an existing stake, not a new position or a significant divestment, indicating relative stability.
Analyst Insight
Investors should note the continued institutional interest from Wasatch Advisors LP, but also research Sangamo's fundamentals and recent performance to understand the context of this holding.
Key Numbers
- 12,397,924 — Shares Owned (Represents the total number of common stock shares of Sangamo Therapeutics held by Wasatch Advisors LP.)
- 7.0% — Percent of Class Owned (Indicates the proportion of Sangamo Therapeutics' common stock owned by Wasatch Advisors LP, showing a significant institutional stake.)
Key Players & Entities
- Wasatch Advisors LP (company) — the reporting person and investment adviser
- Sangamo Therapeutics, Inc. (company) — the issuer of the common stock
- 12,397,924 (dollar_amount) — number of shares owned by Wasatch Advisors LP
- 7.0% (dollar_amount) — percentage of class owned by Wasatch Advisors LP
- February 9, 2024 (date) — date as of change for the filing
Forward-Looking Statements
- Wasatch Advisors LP will maintain a significant stake in Sangamo Therapeutics for the foreseeable future. (Wasatch Advisors LP) — medium confidence, target: 12-24 months
FAQ
Who is the reporting person in this SC 13G/A filing?
The reporting person is Wasatch Advisors LP, an investment adviser registered under section 203 of the Investment Advisers Act of 1940, as stated in Item 1 and Item 3(e) of the filing.
What is the aggregate amount of common stock shares of Sangamo Therapeutics, Inc. owned by Wasatch Advisors LP?
Wasatch Advisors LP owns an aggregate amount of 12,397,924 shares of common stock in Sangamo Therapeutics, Inc., as detailed in Item 9 and Item 4(a) of the filing.
What percentage of Sangamo Therapeutics, Inc.'s common stock does Wasatch Advisors LP own?
Wasatch Advisors LP owns 7.0% of the class of common stock of Sangamo Therapeutics, Inc., as specified in Item 11 and Item 4(b) of the filing.
Does Wasatch Advisors LP have sole or shared voting power over these shares?
Wasatch Advisors LP has sole voting power over all 12,397,924 shares and zero shared voting power, as indicated in Item 5 and Item 4(c)(i) of the filing.
What is the CUSIP number for Sangamo Therapeutics, Inc.'s common stock?
The CUSIP number for Sangamo Therapeutics, Inc.'s common stock is 800677106, as listed in the filing under 'CUSIP Number'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 regarding SANGAMO THERAPEUTICS, INC (SGMO).